Last quarter (Q ), Oncology Pharma's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q, Oncology Pharma's net income was $-81.00K. See Oncology Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 04	Mar 03	Mar 02	Mar 01	Mar 00
Total Revenue	$ 94.00K	$ 1.18M	$ 3.28M	$ 3.67M	$ 4.01M	$ 993.40K
Cost of Revenue	$ 29.00K	$ 654.00K	$ 1.21M	$ 1.36M	$ 1.34M	$ 321.60K
Gross Profit	$ 65.00K	$ 527.00K	$ 2.07M	$ 2.31M	$ 2.67M	$ 671.80K
Operating Expense	$ 650.00K	$ 2.23M	$ 3.69M	$ 4.33M	$ 4.24M	$ 5.42M
Operating Income	$ -585.00K	$ -1.70M	$ -1.63M	$ -2.02M	$ -1.56M	$ -4.75M
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	$ 78.00K	$ 131.00K	$ 85.00K	$ -21.00K	$ -21.00K	$ -15.63K
Pretax Income	-	-	-	-	$ -1.59M	-
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -507.00K	$ -1.56M	$ -1.52M	$ -1.95M	$ -1.59M	$ -4.52M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 679.00K	$ 2.88M	$ 4.91M	$ 5.69M	$ 5.57M	$ 5.74M
Net Income From Continuing And Discontinued Operation	$ -507.00K	$ -1.56M	$ -1.52M	$ -1.95M	$ -1.59M	$ -4.52M
Normalized Income	$ -585.00K	$ -1.70M	$ -1.60M	$ -1.93M	$ -1.57M	$ -4.50M
Interest Expense	-	-	-	-	-	-
EBIT	$ -585.00K	$ -1.70M	$ -1.63M	$ -2.02M	$ -1.56M	$ -4.75M
EBITDA	$ -573.00K	$ -1.62M	$ -1.23M	$ -1.68M	$ -1.10M	$ -4.34M

Currency in USD

Oncology Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing